Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ABBV-303 |
Trade Name | |
Synonyms | ABBV 303|ABBV303 |
Drug Descriptions |
ABBV-303 is a tri-specific natural killer (NK) cell engager that binds to NKG2D and CD16a expressed on NK cells and c-MET expressed on tumor cells and redirects NK cells and CD8+ T-lymphocytes towards MET-expressing tumor cells, potentially resulting in increased tumor cell killing (Cancer Res (2024) 84 (7_Supplement): ND01, NCI Drug Dictionary). |
DrugClasses | MET Immune Cell Therapy 2 |
CAS Registry Number | NA |
NCIT ID | C204983 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ABBV-303 | ABBV-303 | 0 | 1 |
ABBV-303 + Budigalimab | ABBV-303 Budigalimab | 0 | 1 |